左金丸及其主要单体成分抗结直肠癌机制的研究进展

刘霜; 旺建伟

doi:10.13422/j.cnki.syfjx.20232225

您当前的位置：

首页 >

文章列表页 >

左金丸及其主要单体成分抗结直肠癌机制的研究进展

综述 | 更新时间：2023-10-20

- 左金丸及其主要单体成分抗结直肠癌机制的研究进展
  增强出版
- Anti-colorectal Cancer Mechanism of Zuojinwan and Its Main Monomer Components： A Review
- 中国实验方剂学杂志 2023年29卷第22期页码：204-214
- 作者机构：
  
  黑龙江中医药大学，哈尔滨 150040
- 作者简介：
  
  刘霜，在读硕士，从事中药基本理论及组方配伍规律研究，E-mail：3506495966@qq.com
  旺建伟，博士，教授，硕士研究生导师，从事中药基本理论及组方配伍规律研究，E-mail：wangjianweilikai@163.com
- 基金信息：
  
  国家中医药管理局第五批全国中医临床优秀人才研修项目(国中医药人教函［2022］239号);全国中医药创新骨干人才培训项目(国中医药人教函［2019］128号);黑龙江中医药大学优秀青年骨干教师支持计划项目(15041190044)
- DOI：10.13422/j.cnki.syfjx.20232225
  中图分类号： R2-0;R22;R242;R285.5;R287
- 纸质出版日期：2023-11-20，
  
  网络出版日期：2023-10-08，
  
  收稿日期：2023-07-25，
- 稿件说明：
扫描看全文
刘霜,旺建伟.左金丸及其主要单体成分抗结直肠癌机制的研究进展[J].中国实验方剂学杂志,2023,29(22):204-214.

LIU Shuang,WANG Jianwei.Anti-colorectal Cancer Mechanism of Zuojinwan and Its Main Monomer Components： A Review[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(22):204-214.
刘霜,旺建伟.左金丸及其主要单体成分抗结直肠癌机制的研究进展[J].中国实验方剂学杂志,2023,29(22):204-214. DOI： 10.13422/j.cnki.syfjx.20232225.

LIU Shuang,WANG Jianwei.Anti-colorectal Cancer Mechanism of Zuojinwan and Its Main Monomer Components： A Review[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(22):204-214. DOI： 10.13422/j.cnki.syfjx.20232225.

摘要

左金丸为中医经典名方，记载于《丹溪心法》，由黄连和吴茱萸以6∶1比例配伍而成，主治肝火胁痛、胃脘痛、呕吐吞酸等症。现代对左金丸的药理研究很多，尤其是消化道方面，对消化道癌症亦有其独到作用，其抗肿瘤研究主要集中在肠癌、胃癌等。结直肠癌是世界上第3大常见的癌症类型，也是第2大最致命的恶性肿瘤。目前已有多项研究表明左金丸抗结直肠癌的基础药理研究包括结直肠癌的增殖、细胞凋亡、侵袭、能量代谢、表观遗传学和耐药性。生物碱类为左金丸主要活性成分，如小檗碱、吴茱萸碱、黄连碱、巴马汀、吴茱萸次碱等。相较于左金丸对结直肠癌的作用，除无小檗碱对耐药性及吴茱萸碱对能量代谢的研究外，小檗碱和吴茱萸碱还有对肿瘤血管生成、肿瘤促进性炎症反应和肠道菌群的研究。而且黄连碱、巴马汀、吴茱萸次碱可分别调节结直肠癌细胞增殖、凋亡、转移，结直肠癌细胞增殖、凋亡、肿瘤促进性炎症反应，结直肠癌细胞增殖、凋亡、迁移和侵袭。此外，还有研究显示小檗碱和吴茱萸碱联用对结直肠癌细胞的生长、迁移和侵袭有协同增效作用，亦可减弱吴茱萸碱诱导的心脏损伤。因此对近年来左金丸及其主要单体成分抗结直肠癌机制的研究进行归纳总结，以期为今后临床新型高效低毒抗结直肠癌药物研发提供理论依据，为临床实践奠定坚实基础。

Abstract

Zuojinwan is a classic Chinese medicine prescription recorded in the

Danxi's Experiential Therapy

， with Coptidis Rhizoma and Euodiae Fructus

in a ratio of 6 ∶ 1. It can treat symptoms such as liver fire hypochondriac pain， stomach duct pain， vomiting， and acid swallowing. There are many pharmacological studies on Zuojinwan in modern times， especially in the digestive tract， but the prescription also has its unique effect on digestive tract cancer， and its anti-tumor studies mainly focus on colorectal cancer and gastric cancer. Colorectal cancer is the third most common type of cancer in the world and the second deadliest malignancy. At present， a number of studies have shown that the basic pharmacological studies of anti-colorectal cancer by Zuojinwan include the proliferation， apoptosis， invasion， energy metabolism， epigenetics， and drug resistance of colorectal cancer. Alkaloids are the main active ingredients of Zuojinwan， such as berberine， evodiamine， coptisine， palmatine， and rutaecarpine. Compared with the effect of Zuojinwan on colorectal cancer， studies on the effect of berberine and evodiamine on tumor angiogenesis， tumor-promoting inflammation， and intestinal flora are carried out， except the studies on the resistance of berberine and the effect of evodiamine on energy metabolism. In addition， coptisine， palmatine， and rutaecarpine can regulate the proliferation， apoptosis， and metastasis of colorectal cancer cells， the proliferation and apoptosis of colorectal cancer cells， tumor-promoting inflammatory response， and the proliferation， migration， and invasion of colorectal cancer cells， respectively. Moreover， other studies have shown that the combination of berberine and evodiamine can have a synergistic effect on the growth， migration， and invasion of colorectal cancer cells and can reduce the cardiac toxicity induced by evodiamine. Therefore， this paper summarizes the studies on the anti-colorectal cancer mechanism of Zuojinwan and its main monomer components in recent years， so as to provide a theoretical basis for future clinical research and development of new high-efficiency and low-toxicity anti-colorectal cancer drugs and lay a solid foundation for clinical practice.

关键词

左金丸单体成分结直肠癌研究进展

Keywords

Zuojinwanmonomer componentscolorectal cancerresearch progress

references

李艳英，黄能听，韩馥蔓，等.左金丸的古代文献分析［J］.中国实验方剂学杂志，2022，28（12）：39-47.

张骏安，周红祖，梁斌发，等.左金丸的化学成分与药理作用研究进展［J］.药物评价研究，2021，44（12）：2720-2730.

付琳，付强，李冀，等.黄连化学成分及药理作用研究进展［J］.中医药学报，2021，49（2）：87-92.

梁靖蓉，麦凤怡，李陈广，等.吴茱萸碱的药理学研究进展［J］.中国药理学通报，2022，38（10）：1457-1461.

褚璨灿，师为人，陈云志，等.左金丸临床应用与实验研究进展［J］.实用中医药杂志，2019，35（5）：626-629.

曹洋，刘展华，陈志坚.陈锐深教授治疗大肠癌的经验［J］.中医药学刊，2005，23（10）：1750-1751.

李变丽，陈华国，赵超，等.中药抗结直肠癌的作用机制研究进展［J］.天然产物研究与开发，2020，32（12）：2132-2141.

LUQUE C，CEPERO A，PERAZZOLI G，et al.In vitro efficacy of extracts and isolated bioactive compounds from ascomycota fungi in the treatment of colorectal cancer：A systematic review［J］.Pharmaceuticals （Basel），2022，16（1）：22.

DENG J，ZHAO L，YUAN X，et al.Pre-administration of berberine exerts chemopreventive effects in AOM/DSS-induced colitis-associated carcinogenesis mice via modulating inflammation and intestinal microbiota［J］.Nutrients，2022，14（4）：726.

滕之颖，蔡雪婷，杨洋，等.吴茱萸碱对炎症相关性结直肠癌的预防作用研究［J］.南京中医药大学学报，2015，31（3）：234-237.

MA W K，LI H，DONG C L，et al.Palmatine from Mahonia bealei attenuates gut tumorigenesis in ApcMin/+ mice via inhibition of inflammatory cytokines［J］.Mol Med Rep，2016，14（1）：491-498.

XU L，QI Y，LV L，et al.In vitro anti-proliferative effects of Zuojinwan on eight kinds of human cancer cell lines［J］.Cytotechnology，2014，66（1）：37-50.

陈姿含，闫秋莹，顾俊菲，等.小檗碱通过激活自噬诱导caspase依赖性凋亡发挥抗结直肠癌作用（英文）［J］.南京中医药大学学报，2023，39（1）：21-31.

孙强，刘茂伦，杨寒，等.吴茱萸碱通过调控Hedgehog信号通路诱导结直肠癌HCT-116细胞凋亡的研究［J］.中药药理与临床，2022，38（1）：71-77.

PAN J，XU Y，SONG H，et al.Extracts of Zuo Jin Wan，a traditional Chinese medicine， phenocopies 5-HTR1D antagonist in attenuating Wnt/β-catenin signaling in colorectal cancer cells［J］.BMC Complement Altern Med，2017，17（1）：506.

NI L，SUN P，AI M，et al.Berberine inhibited the formation of metastasis by intervening the secondary homing of colorectal cancer cells in the blood circulation to the lung and liver through HEY2［J］.Phytomedicine，2022， doi：10.1016/j.phymed.2022.154303http://dx.doi.org/10.1016/j.phymed.2022.154303.

ZHAO LC，LI J，LIAO K，et al.Evodiamine induces apoptosis and inhibits migration of HCT-116 human colorectal cancer cells［J］.Int J Mol Sci，2015，16（11）：27411-27421.

GUAN X，ZHENG X，VONG C T，et al.Combined effects of berberine and evodiamine on colorectal cancer cells and cardiomyocytes in vitro［J］.Eur J Pharmacol，2020， doi：10.1016/j.ejphar.2020. 173031http://dx.doi.org/10.1016/j.ejphar.2020.173031.

陈宁宁，蒋义芳，杨懿，等.小檗碱与吴茱萸碱联用对结直肠癌细胞迁移、侵袭能力的影响［J］.中国实验方剂学杂志，2022，28（24）：98-104.

熊平，蒋灵芝，许利平.左金丸水煎液和生物碱抗胃溃疡的实验研究［J］.中医药学刊，2004，22（2）：263-263，293.

冯国彬.基于色谱-质谱联用的左金丸和香连丸的化学成分研究［D］.佳木斯：佳木斯大学，2017.

陈文文，过林，贺敏，等.UPLC-DAD/Q-TOF-MS法分析左金丸化学成分［J］.中成药，2017，39（11）：2412-2414.

刘斯琪，王如峰.左金丸组分中药配伍组分制备工艺研究［J］.中草药，2022，53（19）：6001-6011.

LEAL-ESTEBAN L C，FAJAS L.Cell cycle regulators in cancer cell metabolism［J］.Biochim Biophys Acta Mol Basis Dis，2020，1866（5）：165715.

CARNEIRO B A，EL-DEIRY W S.Targeting apoptosis in cancer therapy［J］.Nat Rev Clin Oncol，2020，17（7）：395-417.

潘秋莎.左金丸成分联合益生菌EcN诱导小鼠结直肠癌细胞凋亡的机制研究［D］.上海：上海中医药大学，2019.

FAN J H，XU M M，ZHOU L M，et al.Integrating network pharmacology deciphers the action mechanism of Zuojin capsule in suppressing colorectal cancer［J］.Phytomedicine，2022，doi：10.1016/j.phymed. 2021.153881http://dx.doi.org/10.1016/j.phymed.2021.153881.

GONG C，HU X，XU Y，et al.Berberine inhibits proliferation and migration of colorectal cancer cells by downregulation of GRP78［J］.Anticancer Drugs，2020，31（2）：141-149.

ZHANG Y，LIU X，YU M，et al.Berberine inhibits proliferation and induces G0/G1 phase arrest in colorectal cancer cells by downregulating IGF2BP3［J］.Life Sci，2020，doi：10.1016/j.lfs.2020.118413http://dx.doi.org/10.1016/j.lfs.2020.118413.

GUI Z，LI J，LI J，et al.Berberine promotes IGF2BP3 ubiquitination by TRIM21 to induce G1/S phase arrest in colorectal cancer cells［J］.Chem Biol nteract，2023，doi：10.1016/j.cbi.2023.110408http://dx.doi.org/10.1016/j.cbi.2023.110408.

SHEN Z Q，WANG J，TAN W F，et al.Berberine inhibits colorectal tumor growth by suppressing SHH secretion［J］.Acta Pharmacol Sin，2021，42（7）：1190-1194.

NIE Q，PENG W W，WANG Y，et al.β-catenin correlates with the progression of colon cancers and berberine inhibits the proliferation of colon cancer cells by regulating the β-catenin signaling pathway［J］.Gene，2022，doi：10.1016/j.gene.2022.146207http://dx.doi.org/10.1016/j.gene.2022.146207.

LI S Y，SHI C J，FU W M，et al.Berberine inhibits tumour growth in vivo and in vitro through suppressing the lincROR-Wnt/β-catenin regulatory axis in colorectal cancer［J］.J Pharm Pharmacol，2023，75（1）：129-138.

LIU X，ZHANG Y，WU S，et al.Palmatine induces G2/M phase arrest and mitochondrial-associated pathway apoptosis in colon cancer cells by targeting AURKA［J］.Biochem Pharmacol，2020，doi： 10.1016/j.bcp.2020.113933http://dx.doi.org/10.1016/j.bcp.2020.113933.

HUANG T，XIAO Y，YI L，et al.Coptisine from Rhizoma Coptidis suppresses HCT-116 cells-related tumor growth in vitro and in vivo［J］.Sci Rep，2017， doi：10.1038/srep38524http://dx.doi.org/10.1038/srep38524.

CAO Q，HONG S，LI Y，et al.Coptisine suppresses tumor growth and progression by down-regulating MFG-E8 in colorectal cancer［J］.RSC Adv，2018，8（54）：30937-30945.

HAN B，JIANG P，LI Z，et al.Coptisine-induced apoptosis in human colon cancer cells （HCT-116） is mediated by PI3K/Akt and mitochondrial-associated apoptotic pathway［J］.Phytomedicine，2018，doi： 10.1016/j.phymed.2017.12.027http://dx.doi.org/10.1016/j.phymed.2017.12.027.

ZHANG C，FAN X，XU X，et al.Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon lovo cells［J］.Anticancer Drugs，2010，21（8）：766-776.

LI FS，HUANG J，CUI MZ，et al.BMP9 mediates the anticancer activity of evodiamine through HIF-1α/p53 in human colon cancer cells［J］.Oncol Rep，2020，43（2）：415-426.

CHAN S，SUN R，TU X，et al.Rutaecarpine suppresses the proliferation and metastasis of colon cancer cells by regulating the STAT3 signaling［J］.J Cancer，2022，13（3）：847-857.

BYUN W S，BAE E S，KIM W K，et al.Antitumor activity of rutaecarpine in human colorectal cancer cells by suppression of Wnt/β-catenin signaling［J］.J Nat Prod，2022，85（5）：1407-1418.

DUFF D，LONG A.Roles for RACK1 in cancer cell migration and invasion［J］.Cell Signal，2017，doi： 10.1016/j.cellsig.2017.03.005http://dx.doi.org/10.1016/j.cellsig.2017.03.005.

FARES J，FARES M Y，KHACHFE H H，et al.Molecular principles of metastasis：A hallmark of cancer revisited［J］.Signal Transduct Target Ther，2020，5（1）：28.

ZHOU P，LI X P，JIANG R，et al.Evodiamine inhibits migration and invasion by Sirt1-mediated post-translational modulations in colorectal cancer［J］.Anticancer Drugs，2019，30（6）：611-617.

VIALLARD C，LARRIVEE B.Tumor angiogenesis and vascular normalization：Alternative therapeutic targets［J］.Angiogenesis，2017，20（4）：409-426.

LUO Q，WANG J，ZHAO W，et al.Vasculogenic mimicry in carcinogenesis and clinical applications［J］.J Hematol Oncol，2020，13（1）：19.

张超，荣爱梅，张磊，等.吴茱萸碱对结直肠癌小鼠IL-6R/STAT3通路的影响［J］.西北药学杂志，2022，37（1）：58-64.

GE H，LUO H.Overview of advances in vasculogenic mimicry-a potential target for tumor therapy［J］.Cancer Manag Res，2018， doi：10.2147/CMAR.S164675http://dx.doi.org/10.2147/CMAR.S164675.

QIAO L，LIANG N，ZHANG J，et al.Advanced research on vasculogenic mimicry in cancer［J］.J Cell Mol Med，2015，19（2）：315-326.

LIU Q，QIAO L，LIANG N，et al.The relationship between vasculogenic mimicry and epithelia- mesenchymal transitions［J］.J Cell Mol Med，2016，20（9）：1761-1769.

SUN B，ZHANG D，ZHAO N，et al.Epithelial-to-endothelial transition and cancer stem cells：Two cornerstones of vasculogenic mimicry in malignant tumors［J］.Oncotarget，2017，8（18）：30502-30510.

ZHAO Z，ZENG J，GUO Q，et al.Berberine suppresses stemness and tumorigenicity of colorectal cancer stem-like cells by inhibiting m6A methylation［J］.Front Oncol，2021， doi：10.3389/fonc.2021.775418http://dx.doi.org/10.3389/fonc.2021.775418.

KIM H，YU Y，CHOI S，et al.Evodiamine eliminates colon cancer stem cells via suppressing Notch and Wnt signaling［J］.Molecules，2019，24（24）：4520.

LU X S，SUN W，GE C Y，et al.Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas［J］.Int J Oncol，2013，42（6）：2103-2115.

WANG M，ZHAO X，ZHU D，et al.HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment［J］.J Exp Clin Cancer Res，2017，36（1）：60.

ZENG D，ZHOU P，JIANG R，et al.Evodiamine inhibits vasculogenic mimicry in HCT116 cells by suppressing hypoxia-inducible factor 1-alpha-mediated angiogenesis［J］.Anticancer Drugs，2021，32（3）：314-322.

HANAHAN D，WEINBERG R A. Hallmarks of cancer：The next generation［J］. Cell，2011，144（5）：646-674.

彭孟凡，李鸣，苗晋鑫，等.基于“炎-癌转化”探讨炎症对肿瘤的影响及中医药干预作用［J］.中国实验方剂学杂志，2022，28（22）：196-204.

CHEN H，YE C，WU C，et al.Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut microbiota-mediated lysophosphatidylcholine［J］.Int J Biol Sci，2023，19（7）：2097-2113.

ZHANG Y，ZHANG Y，ZHAO Y，et al.Protection against ulcerative colitis and colorectal cancer by evodiamine via anti-inflammatory effects［J］.Mol Med Rep，2022，25（5）：188.

SENGA S S，GROSE R P.Hallmarks of cancer the new testament［J］.Open Biol，2021，11（1）：200358.

LAO V V，GRADY W M. Epigenetics and colorectal cancer［J］.Nat Rev Gastroenterol Hepatol，2011，8（12）：686-700.

ROSS J P，RAND K N，MOLLOY P L.Hypomethylation of repeated DNA sequences in cancer［J］.Epigenomics，2010，2（2）：245-269.

FODDE R.The APC gene in colorectal cancer［J］.Eur J Cancer，2002，38（7）：867-871.

文彬，熊旻利，戴伟怡，等.左金丸及反左金丸对实验性大肠癌不同时期甲基转移酶表达的影响［J］.世界华人消化杂志，2009，17（20）：2074-2078.

龚艳青，文彬.左金丸对大肠癌APC表达及DNA甲基转移酶活性的影响［J］.南昌大学学报：医学版，2010，50（12）：46-49.

李静，李治国，王花花，等.黄连素与miRNA-29b-3p对结直肠癌细胞增殖和凋亡的影响［J］.癌症进展，2019，17（5）：536-539，544.

张荣枝，廖超，李毅忠.小檗碱单体靶向微小RNA-515-5p基因对结直肠癌细胞增殖和凋亡作用的研究［J］.中国中西医结合消化杂志，2020，28（11）：825-831.

LIU H，HUANG C，WU L，et al.Effect of evodiamine and berberine on miR-429 as an oncogene in human colorectal cancer［J］.Onco Targets Ther，2016，doi：10.2147/OTT.S104729http://dx.doi.org/10.2147/OTT.S104729.

LIU J，PENG Y，WEI W.Cell cycle on the crossroad of tumorigenesis and cancer therapy［J］.Trends Cell Biol，2022，32（1）：30-44.

WANG Y，HE H，CHEN J，et al.Effects of glycolysis and polyamine predation on intestinal epithelial barrier in colorectal cancer［J］.Front Oncol，2022， doi：10.3389/fonc.2022.961257http://dx.doi.org/10.3389/fonc.2022.961257.

余彩雁，靳淑颖，周四桂，等.左金丸对IEC6、HCT116细胞共培养模型肠上皮屏障功能的保护及机制研究［J］.中药新药与临床药理，2023，34（1）：1-7.

MAO L，CHEN Q，GONG K，et al.Berberine decelerates glucose metabolism via suppression of mTOR-dependent HIF-1α protein synthesis in colon cancer cells［J］.Oncol Rep，2018，39（5）：2436-2442.

LIU Y，HUA W，LI Y，et al.Berberine suppresses colon cancer cell proliferation by inhibiting the SCAP/SREBP-1 signaling pathway-mediated lipogenesis［J］.Biochem Pharmacol，2020，doi：10.1016/j.bcp.2019. 113776http://dx.doi.org/10.1016/j.bcp.2019.113776.

LIU Y，FANG X，LI Y，et al.Berberine suppresses the migration and invasion of colon cancer cells by inhibition of lipogenesis through modulation of promyelocytic leukemia zinc finger-mediated sterol-regulatory element binding proteins cleavage-activating protein ubiquitination［J］.J Pharm Pharmacol，2022，74（9）：1353-1363.

YACHIDA S，MIZUTANI S，SHIROMA H，et al.Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer［J］.Nat Med，2019，25（6）：968-976.

HOU H，CHEN D，ZHANG K，et al.Gut microbiota-derived short-chain fatty acids and colorectal cancer：Ready for clinical translation？［J］.Cancer Lett，2022， doi：10.1016/j.canlet.2021.11.027http://dx.doi.org/10.1016/j.canlet.2021.11.027.

YU Y N，YU T C，ZHAO H J，et al.Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment［J］.Oncotarget，2015，6（31）：32013-32026

CHEN H，ZHANG F，ZHANG J，et al.A Holistic view of berberine inhibiting intestinal carcinogenesis in conventional mice based on microbiome-metabolomics analysis［J］.Front Immunol，2020，doi：10.3389/fimmu.2020.588079http://dx.doi.org/10.3389/fimmu.2020.588079.

SUN Q，YANG H，LIU M，et al.Berberine suppresses colorectal cancer by regulation of Hedgeog signaling pathway activity and gut microbiota［J］ .Phytomedicine，2022， doi：10.1016/j.phymed.2022.154227http://dx.doi.org/10.1016/j.phymed.2022.154227.

CHEN H，YE C，CAI B，et al.Berberine inhibits intestinal carcinogenesis by suppressing intestinal pro-inflammatory genes and oncogenic factors through modulating gut microbiota［J］.BMC Cancer 2022，22（1）：566.

WANG H，GUAN L，LI J，et al.The effects of berberine on the Gut microbiota in APC min/+ mice fed with a high fat diet［J］.Molecules，2018，23（9）：2298.

LYAN S，CHANG J，HAO X，et al.Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora［J］.Phytomedicine，2022，doi： 10.1016/j.phymed.2022.154217http://dx.doi.org/10.1016/j.phymed.2022.154217.

ZHU L Q，ZHANG L，ZHANG J，et al.Evodiamine inhibits high-fat diet-induced colitis-associated cancer in mice through regulating the gut microbiota［J］.J Integr Med，2021，19（1）：56-65.

WANG M，ZHOU B，CONG W，et al.Amelioration of AOM/DSS-induced murine colitis-associated cancer by evodiamine intervention is primarily associated with Gut microbiota-metabolism inflammatory signaling axis［J］.Front Pharmacol，2021， doi：10.3389/fphar.2021.797605http://dx.doi.org/10.3389/fphar.2021.797605.

WU Q，YANG Z，NIE Y，et al.Multi-drug resistance in cancer chemotherapeutics：Mechanisms and lab approaches［J］.Cancer Lett，2014，347（2）：159-166.

HANSSEN K M，HABER M，FLETCHER J I.Targeting multidrug resistance-associated protein 1 （MRP-1）-expressing cancers：Beyond pharmacological inhibition［J］.Drug Resist Updat，2021， doi： 10.1016/j.drup.2021.100795http://dx.doi.org/10.1016/j.drup.2021.100795.

付晓伶，隋华，潘树芳，等.左金丸对人结肠癌多药耐药细胞的逆转作用［J］.中华中医药杂志，2014，29（3）：844-847.

付晓伶，隋华，潘树芳，等.左金丸通过ABCB1/P-gp途径对裸鼠人结肠癌多药耐药的抑制作用［J］.上海中医药大学学报，2014，28（2）：47-51.

SUI H，LIU X，JIN B H，et al.Zuo Jin Wan，a traditional Chinese herbal formula，reverses P-gp-mediated MDR in vitro and in vivo［J］.Evid Based Complement Alternat Med，2013，doi： 10.1155/2013/957078http://dx.doi.org/10.1155/2013/957078.

WEI Z，ZHOU J，YU H，et al.Zuo Jin Wan reverses the resistance of colorectal cancer to oxali-platin by regulating the MALAT1/miR-200s/JNK signaling pathway［J］.Evid Based Complement Alternat Med，2022，doi：10.1155/2022/3032407http://dx.doi.org/10.1155/2022/3032407.

SUI H，PAN S F，FENG Y，et al.Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway［J］.BMC Complement Altern Med，2014，doi：10.1186/1472-6882-14 -279http://dx.doi.org/10.1186/1472-6882-14-279.

隋华，卫真真，王子元，等.左金丸调控PI3K/Akt/NF-κB信号通路对人大肠癌干细胞细胞耐药性的影响［J］.上海中医药杂志，2020，54（S1）：127-131.

卫真真，隋华，姜宇朗，等.左金丸联合西妥昔单抗诱导KRAS突变肠癌细胞铁死亡作用研究［J］.中国临床药理学与治疗学，2023，28（2）：130-137.

SUI H，ZHOU L H，ZHANG Y L，et al.Evodiamine suppresses ABCG2 mediated drug resistance by inhibiting p50/p65 NF-κB pathway in colorectal cancer［J］.J Cell Biochem，2016，117（6）：1471-1481.

LI J，MA X，CHAKRAVARTI D，et al.Genetic and biological hallmarks of colorectal cancer［J］.Genes Dev，2021，35（11/12）：787-820.

NGUYEN L H， GOEL A， CHUNG D C. Pathways of colorectal carcinogenesis［J］. Gastroenterology，2020，158（2）：291-302.

CHEN Y X，GAO Q Y，ZOU T H，et al.Berberine versus placebo for the prevention of recurrence of colorectal adenoma：A multicentre，double-blinded，randomised controlled study［J］.Lancet Gastrenterol Hepatol，2020，5（3）：267-275.

FANG S，GUO S，DU S，et al.Efficacy and safety of berberine in preventing recurrence of coloretal adenomas：A systematic review and meta-analysis［J］ .J Ethnopharmacol，2022，dio：10.1016/j.jep.2021.114617.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中药通过NF-κB信号通路干预结直肠癌的研究进展

PI3K/Akt通路调控结直肠癌机制及中医药治疗研究进展

左归丸干预子代先天精亏进展及其“补益先天”探讨

中医药防治糖尿病及其并发症的研究进展